Skip to content

AcuCort is granted a patent in China for the drug ISICORT®

AcuCort AB (Spotlight Stock Market: ACUC) today announced that the China National Intellectual Property Administration has granted the company’s patent application for its drug ISICORT®. The company has an active patent strategy covering all major geographic markets, including China.

ISICORT® is a thin, fast-dissolving and user-friendly oral film for the treatment of acute and severe allergic reactions, for croup in children and chemotherapy-induced nausea and vomiting (CINV). The fast-dissolving oral film contains the glucocorticoid dexamethasone which is a well-known, often used and well-documented anti-inflammatory substance.

“We are very pleased that our patent application for ISICORT® has been granted by the China National Intellectual Property Administration. The positive decision from the Chinese patent authority means that AcuCort now has two active patents that protect the drug ISICORT® in China, which is a major potential market. Furthermore, we continue our partner dialogues and the work for market approval on more markets as planned,” says Jonas Jönmark, CEO of AcuCort AB.

For more information, please contact
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400

The information was submitted for publication, through the agency of the contact person above, on November 3, 2020.

About AcuCort AB (publ)
AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). The bioequivalence study that forms the basis of the application for marketing approval in Europe was carried out with positive results and the Swedish national application was approved by the Swedish Medical Products Agency in October of 2020. Altogether, this strengthens the company’s assessment that the time to commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit